Shandong Xinhua Pharmaceutical Company Limited

Research Shandong Xinhua Pharmaceutical Company Limited (XIN) on Bullrun: market cap EUR 941.60M, P/E 14.9, dividend yield 3.3%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 941.60M; P/E is 14.9; dividend yield is 3.3%.

Peer valuation comparison

Latest P/E is 14.88x versus a Healthcare sector median of 24.46x (39.2% below).

Latest dividend yield is 3.25% versus a Healthcare sector median of 2.11% (54.0% above).

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-28EUR 941.60M14.93.2%0.02

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.02 EUR, yield 3.3%.

About Shandong Xinhua Pharmaceutical Company Limited

Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Shandong Xinhua Pharmaceutical Company Limited's market cap?

Shandong Xinhua Pharmaceutical Company Limited's market capitalization is EUR 941.60M.

What is Shandong Xinhua Pharmaceutical Company Limited's P/E ratio?

Shandong Xinhua Pharmaceutical Company Limited's price-to-earnings (P/E) ratio is 14.9.

Does Shandong Xinhua Pharmaceutical Company Limited pay a dividend?

Shandong Xinhua Pharmaceutical Company Limited has a dividend yield of 3.3%.

What does Shandong Xinhua Pharmaceutical Company Limited do?

Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics.